The subscription period for Dignitana AB's ("Dignitana" or "the Company") rights issue with preferential right for the Company's shareholders ended on 18 December 2018. The rights issue was covered by subscription commitments and guarantees up to 100 percent of the total amount in the Issue, corresponding to approximately SEK 24.3M. 5,383,686 shares, corresponding to 93 percent of the rights issue, was subscribed for with subscription rights and 408,917 shares, corresponding to approximately 7 percent of the rights issue, was subscribed for without subscription rights. In total, 1,517,201 shares were subscribed for without subscription right, implying that the rights issue was subscribed for to approximately 119 percent and the Company will receive approximately SEK 24.3M before issue costs. There will be no need to utilize the guarantee obligations that have been provided.
Allotment of shares subscribed for without subscription rights has been carried out in accordance with the principles set out in the Information Memorandum prepared for the rights issue and published on 3 December 2018. Notification of allotment of shares subscribed for without subscription rights will be sent shortly to those who were granted shares.
In connection with the rights issue, the Company also decided on three directed issues which were fully subscribed. Two directed rights issues amounting to in total approximately SEK 8.1M comprising 1,920,500 shares and one directed off-setting issue amounting to approximately SEK 1.4M comprising in total 337,828 shares. The directed off-setting issue is to off-set the guarantee fee to guarantors in the rights issue.
Through the rights issue and the directed issues, Dignitana's share capital will increase by SEK 8,050,931 to SEK 48,599,155. The number of shares will increase by 8,050,931 to 48,599,155 shares. When the rights issue is registered, BTA will be converted to shares. The new shares are expected to be traded on Nasdaq First North starting in the middle of January 2019.
Redeye AB (redeye.se) is financial advisor and Advokatfirman Delphi is legal advisor in the preferential rights issue, the directed rights issue and the directed off-setting issue. Aktieinvest is the Company's issuing agent in the issues.
This is information that Dignitana AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 08:30 (CET), on 21 December 2018
William Cronin, Chief Executive Officer, Dignitana AB firstname.lastname@example.org +1 469 917 5555
Mikael Wahlgren, Deputy Managing Director, Dignitana AB email@example.com +46 709 33 72 20
About Dignitana AB (publ)
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. Dignitana AB is listed on Nasdaq First North Stockholm in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank is Certified Adviser. Learn more at www.dignitana.se and www.dignicap.com.
Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.
10925 Estate Lane, Suite 185
Dallas, TX 75238
226 60 Lund, Sweden
+46 46 16 30 90